Literature DB >> 19071103

A diagnostic model to differentiate simple steatosis from nonalcoholic steatohepatitis based on the likelihood ratio form of Bayes theorem.

Silvia Sookoian1, Gustavo Castaño, Adriana Laura Burgueño, Tomas Fernández Gianotti, María Soledad Rosselli, Carlos Jose Pirola.   

Abstract

OBJECTIVE: To evaluate the performance of a diagnostic model based on a composite index using clinical and laboratory data, including cardiovascular biomarkers, to help practitioners to differentiate patients with simple steatosis from those with nonalcoholic steatohepatitis (NASH). DESIGN AND METHODS: 101 patients with biopsy proven features of nonalcoholic fatty liver disease were included. We investigated the usefulness of 9 biomarkers in predicting the histological disease severity, including routine biochemical tests, C-reactive protein, soluble intercellular adhesion molecule-1 (sICAM-1) and anthropometric evaluation. Receiver operating characteristic (ROC) curves and likelihood ratios (LRs) were used to evaluate the fit of each test. A composite index was calculated as the product of each individual test LR.
RESULTS: In a model patient who has all positive tests, the post-test probability for NASH would be 99.5%.
CONCLUSION: The capacity of each individual biomarker to independently predict the disease outcome was lower than a composite index constructed after multiplying the LR for each individual test combined into a "multimarker" score.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19071103     DOI: 10.1016/j.clinbiochem.2008.11.005

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  9 in total

1.  [Nonalcoholic steatohepatitis. Predictor and consequence of diabetes].

Authors:  N Stefan; H-U Häring
Journal:  Internist (Berl)       Date:  2011-04       Impact factor: 0.743

2.  Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels?

Authors:  Lucia Carulli; Stefano Ballestri; Amedeo Lonardo; Francesca Lami; Enrico Violi; Luisa Losi; Lisa Bonilauri; Anna Maria Verrone; Maria Rosaria Odoardi; Federica Scaglioni; Marco Bertolotti; Paola Loria
Journal:  Intern Emerg Med       Date:  2011-05-11       Impact factor: 3.397

Review 3.  Advances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics.

Authors:  Simona Riccio; Rosa Melone; Caterina Vitulano; Pierfrancesco Guida; Ivan Maddaluno; Stefano Guarino; Pierluigi Marzuillo; Emanuele Miraglia Del Giudice; Anna Di Sessa
Journal:  World J Clin Pediatr       Date:  2022-03-23

4.  Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study.

Authors:  Ariel E Feldstein; Anna Wieckowska; A Rocio Lopez; Yao-Chang Liu; Nizar N Zein; Arthur J McCullough
Journal:  Hepatology       Date:  2009-10       Impact factor: 17.425

5.  Noninvasive markers: a double-edged sword that stratifies nonalcoholic steatohepatitis.

Authors:  Goh Eun Chung; Donghee Kim
Journal:  Clin Mol Hepatol       Date:  2013-06-27

6.  Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD.

Authors:  Steven G Pearce; Nirav C Thosani; Jen-Jung Pan
Journal:  Biomark Res       Date:  2013-02-04

Review 7.  Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity.

Authors:  Carlos J Pirola; Silvia Sookoian
Journal:  World J Gastroenterol       Date:  2018-04-21       Impact factor: 5.742

Review 8.  The OMICs Window into Nonalcoholic Fatty Liver Disease (NAFLD).

Authors:  Lucia Carulli; Giulia Zanca; Filippo Schepis; Erica Villa
Journal:  Metabolites       Date:  2019-02-01

9.  Correlations between PNPLA3 Gene Polymorphisms and NAFLD in Type 2 Diabetic Patients.

Authors:  Oana Irina Gavril; Lidia Iuliana Arhire; Radu Sebastian Gavril; Madalina Ioana Zota; Andreea Gherasim; Otilia Nita; Andrei Drugescu; Andrei Catalin Oprescu; Irina Mihaela Esanu; Florin Mitu; Mariana Graur; Laura Mihalache
Journal:  Medicina (Kaunas)       Date:  2021-11-15       Impact factor: 2.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.